clinical trial · NCT06539195
DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9)
Diffuse Large B Cell LymphomaDZD8586DZD8586DZD8586
brief summary
This study will treat patients with DLBCL whose disease comes back or is not responding to prior therapy. This study will assess the anti-tumor activity of DZD8586 as monotherapy. It will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body.
started
Mar 13, 2024
primary completion
Dec 1, 2026
completion
Dec 1, 2026
last updated
Mar 4, 2026
official title
A Phase 2, Open-label, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol